Bevacizumab in Treating Patients With Angiosarcoma
Completed · Phase 2
Conditions studied: Sarcoma
In brief
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well bevacizumab works in treating patients with angiosarcoma.
Key facts
- Study ID
- NCT00288015
- Run by
- Northwestern University
- People needed
- 32
- Starts
- 2005-10-01
- Expected to finish
- 2016-11-10
- Last updated by the study team
- 2018-06-25
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Rebecca and John Moores UCSD Cancer Center — La Jolla, California, United States
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University — Chicago, Illinois, United States
- Mayo Clinic Cancer Center — Rochester, Minnesota, United States
- Fox Chase Cancer Center CCOP Research Base — Philadelphia, Pennsylvania, United States
- M. D. Anderson Cancer Center at University of Texas — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.